Waiting to educate individuals about genetic information until they are in a clinic as patients (or parents of patients), in a laboratory as research participants, or in an attorney’s office or administrative setting facing specific, life-altering decisions (from end-of-life care in light of APOE4 Alzheimer disease risks to participation in competitive sports in light of sudden cardiac arrest risks) is simply too late. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.